Effects of L-carnitine combined with pancreatic kininogenase on thioredoxin 2, thioredoxin reductase 1, and sperm quality in patients with oligoasthenospermia.
L-carnitine (LC)
oligoasthenospermia
pancreatic kininogenase
thioredoxin 2 (Trx 2)
thioredoxin reductase 1 (TrxR 1)
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
17
06
2021
accepted:
18
08
2021
entrez:
17
9
2021
pubmed:
18
9
2021
medline:
18
9
2021
Statut:
ppublish
Résumé
To study the effects of L-carnitine (LC) combined with pancreatic kininogenase on thioredoxin 2 (Trx 2), thioredoxin reductase 1 (TrxR 1), and sperm quality in patients with oligoasthenospermia. A total of 300 male infertility patients with oligoasthenospermia who were treated in the andrology clinic of our hospital from December 2019 to December 2020 were randomly divided into an LC group and combined treatment group, and 50 males with normal semen were selected as a control group. The computer-assisted semen analysis system (CASA) was used to detect the total number, vitality, and forward motility of the sperm before and after treatment, and sperm morphology was detected by the Diff-Quik method of the sperm staining kit. Sperm chromatin dispersion (SCD) method was used to detect sperm DNA fragments, and Western-blot was used to detect the protein expression of Trx 2 and TrxR 1. There were no significant differences in sperm density, motility rate, forward motile sperm rate, and DNA fragmentation rate in oligoasthenospermia patients before treatment (P>0.05). However, after 1 month of treatment, the sperm density, motility rate, and forward motile sperm rate were all higher than before treatment (P<0.05), while the DNA fragmentation rate was lower than before treatment. At the same time, each index of semen in the combination group was higher than that in the LC group (P<0.05), and the total effective rate in the combination group was significantly higher than in the LC group (P<0.01). The expression of Trx2 protein in oligoasthenospermia patients was significantly increased (P<0.05), while the expression of TrxR1 protein was significantly decreased (P<0.05). After 3 months of treatment, the expression of Trx2 protein was significantly decreased (P<0.05), while the expression of TrxR1 protein was significantly increased (P<0.05). The results suggest Trx 2 and TrxR 1 may be candidate protein markers for oligoasthenospermia. LC combined with pancreatic kininogenase in the treatment of male oligoasthenospermia can effectively promote sperm maturation, enhance sperm motility, and improve semen quality, which has high application value.
Sections du résumé
BACKGROUND
BACKGROUND
To study the effects of L-carnitine (LC) combined with pancreatic kininogenase on thioredoxin 2 (Trx 2), thioredoxin reductase 1 (TrxR 1), and sperm quality in patients with oligoasthenospermia.
METHODS
METHODS
A total of 300 male infertility patients with oligoasthenospermia who were treated in the andrology clinic of our hospital from December 2019 to December 2020 were randomly divided into an LC group and combined treatment group, and 50 males with normal semen were selected as a control group. The computer-assisted semen analysis system (CASA) was used to detect the total number, vitality, and forward motility of the sperm before and after treatment, and sperm morphology was detected by the Diff-Quik method of the sperm staining kit. Sperm chromatin dispersion (SCD) method was used to detect sperm DNA fragments, and Western-blot was used to detect the protein expression of Trx 2 and TrxR 1.
RESULTS
RESULTS
There were no significant differences in sperm density, motility rate, forward motile sperm rate, and DNA fragmentation rate in oligoasthenospermia patients before treatment (P>0.05). However, after 1 month of treatment, the sperm density, motility rate, and forward motile sperm rate were all higher than before treatment (P<0.05), while the DNA fragmentation rate was lower than before treatment. At the same time, each index of semen in the combination group was higher than that in the LC group (P<0.05), and the total effective rate in the combination group was significantly higher than in the LC group (P<0.01). The expression of Trx2 protein in oligoasthenospermia patients was significantly increased (P<0.05), while the expression of TrxR1 protein was significantly decreased (P<0.05). After 3 months of treatment, the expression of Trx2 protein was significantly decreased (P<0.05), while the expression of TrxR1 protein was significantly increased (P<0.05).
CONCLUSIONS
CONCLUSIONS
The results suggest Trx 2 and TrxR 1 may be candidate protein markers for oligoasthenospermia. LC combined with pancreatic kininogenase in the treatment of male oligoasthenospermia can effectively promote sperm maturation, enhance sperm motility, and improve semen quality, which has high application value.
Identifiants
pubmed: 34532275
doi: 10.21037/tau-21-680
pii: tau-10-08-3515
pmc: PMC8421838
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3515-3523Informations de copyright
2021 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tau-21-680). The authors have no conflicts of interest to declare.
Références
Arch Ital Urol Androl. 2020 Oct 02;92(3):
pubmed: 33016059
Free Radic Biol Med. 2011 Jul 1;51(1):69-77
pubmed: 21440059
Int J Reprod Biomed. 2018 Jun 13;17(5):
pubmed: 31435617
Theriogenology. 2020 Mar 15;145:59-66
pubmed: 31986302
Reprod Biomed Online. 2019 Aug;39(2):269-279
pubmed: 31160241
Acta Pharmacol Sin. 2020 Dec;41(12):1597-1608
pubmed: 32300244
Free Radic Biol Med. 2019 Sep;141:159-171
pubmed: 31212063
Zhonghua Nan Ke Xue. 2017 Apr;23(4):367-371
pubmed: 29714424
Free Radic Biol Med. 2016 Aug;97:375-385
pubmed: 27377780
Asian J Androl. 2018 Sep-Oct;20(5):448-453
pubmed: 29676291
Kidney Blood Press Res. 2016;41(1):9-17
pubmed: 26751697
Andrology. 2018 Jan;6(1):236-246
pubmed: 28973833
Andrologia. 2017 Dec;49(10):
pubmed: 28124476
Acta Clin Croat. 2019 Sep;58(3):508-515
pubmed: 31969764
Transl Androl Urol. 2020 Mar;9(Suppl 2):S239-S243
pubmed: 32257864
Am J Physiol Heart Circ Physiol. 2015 Feb 15;308(4):H291-302
pubmed: 25485897
Andrology. 2016 Sep;4(5):800-7
pubmed: 27152678
Free Radic Biol Med. 2019 Aug 20;140:28-35
pubmed: 30862542
Aging Male. 2020 Dec;23(5):592-598
pubmed: 31070084
Urologiia. 2019 Sep;(4):62-68
pubmed: 31535807
Free Radic Biol Med. 2018 Feb 20;116:123-128
pubmed: 29305108
Cryo Letters. 2015 May-Jun;36(3):182-6
pubmed: 26510336